综合分析显示喉鳞状细胞癌中p16/CDKN2A表达与治疗结局无显著相关性
研究纳入癌症基因组图谱(TCGA)和马里兰大学医学中心(UMMC)共310例喉癌患者,分析p16蛋白表达与生存结局的关联。TCGA队列中高p16蛋白表达者无病生存(DFS)概率为89%,低表达组为51%(p=0.0266),但多因素分析未确立p16为独立预后因素。
要点
- TCGA队列中高p16蛋白表达者DFS概率89%,低表达组51%(p=0.0266)。
- 平均相对p16蛋白表达随TNM分期进展显著降低:II期1.116、III期1.075、IV期0.6204。
- 多因素分析未确立p16为独立预后因素,其作为独立预后标志物的效用需进一步验证。
核心结论
- 研究观察到低p16蛋白表达与更长DFS和晚期TNM分期相关的趋势,但多因素分析未确立p16为独立预后因素。
- p16可能在肿瘤进展中具有生物学作用,但其作为临床结局独立预后标志物的效用需进一步验证。
研究设计与样本
- 研究纳入来自癌症基因组图谱(TCGA)计划和马里兰大学医学中心(UMMC)的310例喉癌患者队列,分析p16表达与生存结局的关联。
主要发现
- TCGA队列中高p16蛋白表达患者DFS概率为89%,低p16蛋白组为51%(p=0.0266)。
- 平均相对p16蛋白表达随TNM分期进展显著降低:II期1.116、III期1.075、IV期0.6204;II期 vs III期 p=0.7871,III期 vs IV期 p=0.0065,I期 vs IV期 p=0.0031。
- p16蛋白表达与CDKN2A保留/缺失状态相关(p=0.0077),CDKN2A保留患者DFS高于CDKN2A缺失患者(p=0.0187)。
- UMMC和TCGA队列多因素分析显示,患者年龄增加和较高T分期均显著增加死亡风险(分别为p=0.05、p=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多因素分析未确立p16为独立预后因素,其作为独立预后标志物的效用需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The p16/CDKN2A protein is being explored as an independent prognostic marker in laryngeal cancer, with studies suggesting that p16-positive patients may have a better prognosis. While its role is well-established in oropharyngeal squamous cell carcinoma (OPSCC) related to HPV, ongoing research indicates its potential prognostic value in laryngeal cancer, even in HPV-negative cases. METHODS: In this study, we investigated the association between survival outcomes and p16 expression in a cohort of 310 laryngeal cancer patients from the Cancer Genome Atlas (TCGA) Program and the University of Maryland Medical Center (UMMC). RESULTS: In the TCGA cohort, patients with high p16 protein expression had a significantly higher probability of disease-free survival (DFS) at 89%, compared to 51% in the low p16 protein group (p = 0.0266). Additionally, the mean relative p16 protein expression decreased significantly with advancing TNM stage, measured at 1.116 for stage II, 1.075 for stage III, and 0.6204 for stage IV (p = 0.7871 for stage II vs. stage III, p = 0.0065 for stage III vs. stage IV, p = 0.0031 for stage I vs. stage IV). Protein expression for p16 also correlated with CDKN2A retention/deletion status (p = 0.0077), where the DFS was higher in patients with retained CDKN2A than those with deleted CDKN2A (p = 0.0187). Multivariate analysis of the UMMC and TCGA cohorts revealed that both an increase in the patient's age and higher T stage significantly increased the risk of mortality (p = 0.05, p = 0.01, respectively). CONCLUSION: While this study observes trends suggesting that low p16 protein expression is associated with longer DFS and advanced TNM stage in laryngeal cancer, the multivariate analysis did not establish p16 as an independent prognostic factor. These findings suggest that while p16 may have a biological role in tumor progression, its utility as a standalone prognostic marker in clinical outcomes requires further validation.
引用
- Nguyen HH, Gupta I, Cellini A, et al. Comprehensive Analysis Reveals No Significant Correlation Between p16/ CDKN2A Expression and Treatment Outcomes in Laryngeal Squamous Cell Carcinoma. Head Neck. 2024. PMID: 39714101. doi:10.1002/hed.28044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。